Functional polymorphisms in apoptosis pathway genes and survival in patients with gastric cancer

Environmental and Molecular Mutagenesis

Volumn 55, Issue 5, 2014, Pages 421-427

  Gu, Dongying ^a   Du, Mulong ^b,c   Tang, Cuiju ^a   Chu, Haiyan ^b,c   Xu, Zhi ^a   Huo, Xinyin ^a   Gong, Weida ^d   Tang, Yongfei ^e   Zhou, Jianwei ^b   Tong, Na ^b   Xu, Yong ^a   Zhang, Zhengdong ^b,c   Wang, Meilin ^b,c   Chen, Jinfei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c Nanjing Medical University   (China)

^d Yixing Cancer Hospital   (China)

^e YIXING PEOPLE S HOSPITAL   (China)

Author keywords

Apoptosis; CASP8; FAS FASL; Gastric cancer survival; Single nucleotide polymorphisms

Indexed keywords

FAS LIGAND;

ADULT; ALLELE; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHINESE; DEATH; DISTANT METASTASIS; FEMALE; GENOTYPE; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROMOTER REGION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TUMOR INVASION; TUMOR VOLUME;

APOPTOSIS; CASP8; FAS/FASL; GASTRIC CANCER SURVIVAL; SINGLE-NUCLEOTIDE POLYMORPHISMS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; APOPTOSIS; CASPASE 8; FAS LIGAND PROTEIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84901837730     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.21856     Document Type: Article

References (31)

1. Ahn JR, Jung M, Kim C, Hong MH, Chon HJ, Kim HR, Jeung HC, Hyung WJ, Lee SS, Chung HC, et al. 2009. Prognosis of pN3 stage gastric cancer. Cancer Res Treat 41:73-79.
2. Becker KF, Keller G, Hoefler H. 2000. The use of molecular biology in diagnosis and prognosis of gastric cancer. Surg Oncol 9:5-11.
3. Danial NN, Korsmeyer SJ. 2004. Cell death: Critical control points. Cell 116:205-219.
4. Evan GI, Vousden KH. 2001. Proliferation, cell cycle and apoptosis in cancer. Nature 411:342-348.
5. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917.
6. Frank B, Rigas SH, Bermejo JL, Wiestler M, Wagner K, Hemminki K, Reed MW, Sutter C, Wappenschmidt B, Balasubramanian SP, et al. 2008. The CASP8 -652 6N del promoter polymorphism and breast cancer risk: A multicenter study. Breast Cancer Res Treat 111:139-144.
7. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189-1192.
8. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. 2009. Gastric cancer. Lancet 374:477-490.
9. Hengartner MO. 2000. The biochemistry of apoptosis. Nature 407:770-776.
10. Hsu PI, Lu PJ, Wang EM, Ger LP, Lo GH, Tsay FW, Chen TA, Yang HB, Chen HC, Lin WS, et al. 2008. Polymorphisms of death pathway genes FAS and FASL and risk of premalignant gastric lesions. Anticancer Res 28:97-103.
11. Huang QR, Morris D, Manolios N. 1997. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 34:577-582.
12. Lauren P. 1965. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31-49.
13. Li C, Zhao H, Hu Z, Liu Z, Wang LE, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, et al. 2008. Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat 29:1443-1451.
14. Li Q, Peng J, Li XH, Liu T, Liang QC, Zhang GY. 2010. Clinical significance of Fas and FasL protein expression in gastric carcinoma and local lymph node tissues. World J Gastroenterol 16:1274-1278.
15. Liamarkopoulos E, Gazouli M, Aravantinos G, Tzanakis N, Theodoropoulos G, Rizos S, Nikiteas N. 2011. Caspase 8 and caspase 9 gene polymorphisms and susceptibility to gastric cancer. Gastric Cancer 14:317-321.
16. Lowe SW, Lin AW. 2000. Apoptosis in cancer. Carcinogenesis 21:485-495.
17. Ohno S, Tachibana M, Shibakita M, Dhar DK, Yoshimura H, Kinugasa S, Kubota H, Masunaga R, Nagasue N. 2000. Prognostic significance of Fas and Fas ligand system-associated apoptosis in gastric cancer. Ann Surg Oncol 7:750-757.
18. Opferman JT. 2008. Apoptosis in the development of the immune system. Cell Death Differ 15:234-242.
19. Pingoud-Meier C, Lang D, Janss AJ, Rorke LB, Phillips PC, Shalaby T, Grotzer MA. 2003. Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin Cancer Res 9:6401-6409.
20. Sasaki T, Maeda Y, Mukoyama O. 2002. Guideline for proper use of antineoplastic agents. Cancer of the digestive system-Malignant cancers (stomach, colonic, and pancreatic cancers). Gan To Kagaku Ryoho 29:1008-1014.
21. Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, Skibola CF, Smith MT, Morgan GJ. 2003. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 63:4327-4330.
22. Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, Guo Y, Yang M, Zhang X, Zhang Q, et al. 2007. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 39:605-613.
23. Tian J, Pan F, Li J, Ma Y, Cen H, Pan HF, Pan YY, Ye DQ. 2012. Association between the FAS/FASL polymorphisms and gastric cancer risk: A meta-analysis. Asian Pac J Cancer Prev 13:945-951.
24. Tinhofer I, Wykypiel H, Marschitz I, Henn T, Greil R. 2000. Gastric cancer cell lines lack Fas ligand (FasL) expression but kill T cells via a FasL independent pathway. Gut 46:738-740.
25. Wang M, Bai J, Tan Y, Wang S, Tian Y, Gong W, Zhou Y, Gao Y, Zhou J, Zhang Z. 2011. Genetic variant in PSCA predicts survival of diffuse-type gastric cancer in a Chinese population. Int J Cancer 129:1207-1213.
26. Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, Cooke J, Xie F, Cooper GS, Kimberly RP. 2003. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: A candidate background gene in African American systemic lupus erythematosus patients. J Immunol 170:132-138.
27. Xiao HW, Lai XY, Luo Y, Shi JM, Tan YM, He JS, Xie WZ, Li L, Zhu XL, Zhu JJ, et al. 2011. Relationship between TNFA, TNFB and TNFRII gene polymorphisms and outcome after unrelated hematopoietic cell transplantation in a Chinese population. Bone Marrow Transplant 46:400-407.
28. Yoo SS, Choi JE, Lee WK, Choi YY, Kam S, Kim MJ, Jeon HS, Lee EB, Kim DS, Lee MH, et al. 2009. Polymorphisms in the CASPASE genes and survival in patients with early-stage non-small-cell lung cancer. J Clin Oncol 27:5823-5829.
29. Zhang W, Li C, Wang J, He C. 2012. Functional polymorphisms in FAS/FASL system contribute to the risk of occurrence but not progression of gastric cardiac adenocarcinoma. Hepatogastroenterology 59:141-146.
30. Zhang ZF, Kurtz RC, Yu GP, Sun M, Gargon N, Karpeh M, Jr., Fein JS, Harlap S. 1997. Adenocarcinomas of the esophagus and gastric cardia: The role of diet. Nutr Cancer 27:298-309.
31. Zhou RM, Wang N, Chen ZF, Duan YN, Sun DL, Li Y. 2010. Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma. J Gastroenterol Hepatol 25:555-561.